Nectar Lifesciences Limited share price
NSE: NECLIFE · ISIN INE023H01027
Key numbers
- Market cap
- ₹ 211 Cr
- Current price
- ₹ 10.84
- 52-week high / low
- ₹ 22 / 9
- Stock P/E
- -
- Book value
- ₹ 29.0
- Dividend yield
- 0.00%
- ROCE
- -8.3%
- ROE
- -38.1%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- -
- Profit growth (3 yrs)
- -
- 1-year return
- -27.9%
About Nectar Lifesciences Limited
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Further. It exports its poducts. Nectar Lifesciences Limited was incorporated in 1995 and is based in Chandigarh, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 0 | 5 | 0 | 0 | 0 |
| Operating profit | -0 | -0 | -2 | -57 | -27 |
| Net profit | -63 | -0 | 14 | -68 | -15 |
| EPS (₹) | -2.82 | -7.85 | 0.64 | -3.38 | -0.79 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.